VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2022 | FFCD 1709-SIRTCI: selective internal radiation therapy + xelox, bevacizumab and atezolizumab in mCRC

David Tougeron, MD, PhD, Poitiers University Hospital, Poitiers, France, provides an overview of the ongoing Phase II FFCD 1709-SIRTCI (NCT04659382) trial evaluating the safety and efficacy of selective internal radiation therapy plus xelox, bevacizumab and atezolizumab in liver-dominant metastatic colorectal cancer (mCRC). The primary outcome is progression-free survival (PFS). This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter